振东制药(300158) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 115,000 and 135,000 thousand yuan for the fiscal year 2024, compared to a loss of 4,398.41 thousand yuan in the same period last year [3]. - The net loss after deducting non-operating gains and losses is projected to be between 57,000 and 79,000 thousand yuan, compared to a loss of 11,606.41 thousand yuan in the previous year [3]. - The expected impact of non-operating gains and losses on the net profit attributable to shareholders is approximately -56,000 to -58,000 thousand yuan, significantly down from an impact of 7,208 thousand yuan in the same period last year [6]. Impairment and Fair Value Losses - The company has recognized impairment provisions for receivables from Beijing Landy Pharmaceutical Co., which are expected to be unrecoverable due to arbitration disputes [6]. - The company has also recorded fair value losses on trust assets due to overdue receivables from a subsidiary, impacting the overall financial performance [5]. - The impairment assessment for asset impairment provisions is ongoing and will be finalized based on the accounting firm's audit results [6]. Operational Status and Market Conditions - The production and operational activities of the company remain normal, but sales and prices of some main products have declined due to industry policies and market conditions [6]. - The company plans to disclose detailed financial data in the 2024 annual report, as the current figures are preliminary estimates [7]. Investor Advisory - Investors are advised to make cautious decisions and be aware of investment risks [8]. - The company has communicated with the accounting firm regarding the performance forecast, and there are no discrepancies noted [4].